Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vitamin D Repletion in Stone Formers With Hypercalciuria

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
David E. Leaf, New York Presbyterian Hospital
ClinicalTrials.gov Identifier:
NCT01295879
First received: February 14, 2011
Last updated: September 10, 2012
Last verified: September 2012
  Purpose

Vitamin D plays a critical role in maintaining bone health, as well as preventing cardiovascular disease, cancer, and various autoimmune diseases, such as diabetes. Vitamin D deficiency is very common in the United States and worldwide, and is now being increasingly recognized and treated. One group in which vitamin D deficiency may be particularly important is patients who have had kidney stones. These patients frequently have elevated levels of calcium in their urine, which is a common and important risk factor for calcium containing kidney stones. Because vitamin D increases absorption of calcium into the blood by the intestines, physicians may be reluctant to prescribe vitamin D therapy to patients with vitamin D deficiency if they also have kidney stones and high amounts of calcium in the urine. They are concerned about the possible risk of increasing the amount of calcium in the urine (and thereby increasing the risk of calcium stones occurring again). However, studies in patients without kidney stones, as well as studies in patients with high calcium levels in the urine, have demonstrated that giving vitamin D is effective and safe and does not increase calcium in the urine. Therefore, the investigators will study the effects of giving vitamin D on the amount of calcium in the urine in patients with a history of kidney stones and elevated calcium in the urine. The investigators will evaluate the safety of giving vitamin D to this particular group of patients.


Condition Intervention Phase
Nephrolithiasis
Urolithiasis
Idiopathic Hypercalciuria
Vitamin D Deficiency
Disorder of Vitamin D
Drug: Ergocalciferol
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Ergocalciferol Repletion on Urine Calcium Among Stone Formers With Vitamin D Deficiency and Hypercalciuria

Resource links provided by NLM:


Further study details as provided by New York Presbyterian Hospital:

Primary Outcome Measures:
  • Change in 24 Hour Urine Calcium [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    Elevated values of urine calcium are a risk factor for recurrence of calcium kidney stones


Secondary Outcome Measures:
  • Change in 24 Hour Urine Supersaturation of Calcium Oxalate [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    Elevated values of calcium oxalate supersaturation in the urine are a risk factor for recurrence of calcium kidney stones

  • Recurrence of Kidney Stones [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 30
Study Start Date: September 2010
Study Completion Date: June 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ergocalciferol
Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks
Drug: Ergocalciferol
Ergocalciferol 50,000 IU's orally per week, for 8 weeks
Other Name: Vitamin D2

Detailed Description:

The investigators plan to conduct a clinic-based interventional study of 30 patients followed at outpatient urology clinics associated with New York Presbyterian Hospital (NYPH). The intervention is supplementation with oral ergocalciferol 50,000 IU per week for 8 weeks, and each participant will serve as his/her own control. The formulation, dose, and duration of vitamin D therapy is reflective of that which is given in routine clinical practice to patients with vitamin D deficiency. The outcome is the change in urinary calcium excretion.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of nephrolithiasis as per medical record
  • Urinary calcium excretion between 150 and 400 mg/day (measured within 3 months of study enrollment)
  • 25(OH)D deficiency or insufficiency (defined as a serum level < 30 ng/ml) within 3 months of enrollment

Exclusion Criteria:

  • Pregnant women, since the optimal dose of vitamin D supplementation in this population has not been rigorously studied.
  • Known uric acid, cystine, or struvite stone disease (because our intervention is predominantly aimed at patients with calcium stone disease). An exception to this is patients who have passed both uric acid and calcium stones, or patients who have passed stones of mixed composition (uric acid and calcium).
  • Hypercalcemia (serum calcium > 10.4 mg/dL) at baseline
  • Acute stone event or gross hematuria (blood in the urine) within the past 2 months
  • Recent stone intervention within the past 1 month
  • Suspected or known secondary causes of hypercalciuria, such as primary hyperparathyroidism, sarcoidosis, hyperthyroidism, or malignancy (except nonmelanoma skin cancer)
  • Addition or dose change of medicines potentially affecting urinary calcium since the baseline 24hour urine collection (including diuretics, magnesium supplements, potassium supplements, potassium citrate, and vitamin D supplementation)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01295879

Locations
United States, New York
New York Presbyterian Hospital
New York, New York, United States, 10032
Sponsors and Collaborators
New York Presbyterian Hospital
  More Information

No publications provided

Responsible Party: David E. Leaf, Nephrology Fellow, New York Presbyterian Hospital
ClinicalTrials.gov Identifier: NCT01295879     History of Changes
Other Study ID Numbers: AAAF3346
Study First Received: February 14, 2011
Results First Received: September 10, 2012
Last Updated: September 10, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by New York Presbyterian Hospital:
Vitamin D insufficiency

Additional relevant MeSH terms:
Hypercalciuria
Nephrolithiasis
Urolithiasis
Vitamin D Deficiency
Avitaminosis
Deficiency Diseases
Kidney Diseases
Malnutrition
Nutrition Disorders
Signs and Symptoms
Urologic Diseases
Urological Manifestations
Ergocalciferols
Vitamin D
Vitamins
Bone Density Conservation Agents
Growth Substances
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 25, 2014